Sai Life Sciences Reports Strong Start to FY27

Hyderabad, August 06, 2026: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), one of India’s fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the first quarter ended 30 June 2026.

Commenting on the performance during the quarter, Mr. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said, “We are pleased with the progress made during the quarter and the momentum we continue to see across the business. There is a clear evolution in what large pharmaceutical companies are looking for from their outsourcing partners. The expectation is for strong, scientifically led partners who can take greater ownership of integrated discovery and development programs, rather than simply execute individual pieces of work. We believe that the combination of our technology base, scientific talent and culture is a key reason why large pharmaceutical companies are increasingly bringing significant work to Sai through strategic engagements. These engagements will create a healthy and sustained pipeline over multiple years."

Mr. Siva Chittor, Chief Financial Officer, Sai Life Sciences Limited added, “We have begun FY27 on a healthy note, delivering revenue of ₹554 crore in Q1, up 12% year-on-year, with growth across both our CRO and CDMO businesses. CRO maintained strong momentum, growing 24% year-on-year, while our CMC pipeline continues to strengthen with 33 active commercial molecules and 14 late-phase molecules. Coupled with encouraging traction in our FTE-led engagement model, a healthy balance sheet and disciplined capital allocation, we remain confident in executing our long-term growth strategy.”

Financial Performance:

Particulars (₹ crores)	Q1FY27	Q1FY26	YoY%
Revenue from Operations	554	496	12%
EBITDA^	148	125	18%
EBITDA Margin%	27%	25%
PAT	73	60	22%
PAT Margin%	13%	12%

    Note: ^including forex

Key Highlights

• Revenue from Operations was ₹554 Cr for Q1FY27 compared to ₹496 Cr in Q1FY26, an increase of 12%.
• EBITDA stood at ₹148 Cr for Q1FY27 compared to ₹125 Cr in Q1FY26, an increase of 18%.
• PAT stood at ₹73 Cr for Q1FY27 compared to ₹60 Cr in Q1FY26, an increase of 22%.
• Operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad.

Achieved EcoVadis Platinum Rating for sustainability, joining the top 1% of companies assessed worldwide

About Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE)

Sai Life Sciences is one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Headquartered in Hyderabad, India, with a strong global presence, the company offers integrated solutions spanning discovery, process development, clinical and commercial manufacturing, and advanced technology platforms. Sai Life Sciences is committed to delivering high-quality, cost-effective, and scalable solutions while upholding the highest standards of safety, compliance, and integrity. With a focus on innovation and operational excellence, the company continues to strengthen its capabilities to support emerging therapeutic modalities and meet the evolving needs of the life sciences industry.

For more information, please visit www.sailife.com

For further details, please feel free to contact: Investorrelation@sailife.com

Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Sai Life, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.